146 results about "Spectrum disorder" patented technology

The invention relates to compositions and methods for treating mood spectrum disorder. The compositions relate to novel combinations and formulations of pharmaceutical compounds for treatment of mood spectrum disorders. The methods provide for use of the compounds provided herein for the treatment of mood spectrum disorders in addition to the use of mood screens for diagnosing a patient.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful NI for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention relates to compositions and methods for treating mood spectrum disorder. The compositions relate to novel combinations and formulations of pharmaceutical compounds for treatment of mood spectrum disorders. The methods provide for use of the compounds provided herein for the treatment of mood spectrum disorders in addition to the use of mood screens for diagnosing a patient.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, tinnitus, status epilepticus.

Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present invention provides methods of diagnosing and / or predicting autism spectrum disorder comprising determining the presence of microdeletions and microduplications on chromosomes 15 and 16.

The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD, and methods for determining the risk that a mother's future offspring will develop an a neurodevelopmental disorder, including an ASD.

Disclosed are methods and systems and methods for non-invasive neuromodulation using ultrasound for the Treatment of Autism Spectrum Disorders and Alzheimer's Disease and other dementias. The neuromodulation can produce acute or long-term effects. The latter occur through Long-Term Depression (LTD) and Long-Term Potentiation (LTP) via training. Included is control of direction of the energy emission, intensity, frequency, pulse duration, firing pattern, and phase / intensity relationships to targeting and accomplishing up regulation and / or down regulation.

A therapeutic method for developing the ability of subjects with autism spectrum disorders to produce and perceive spoken language, including sequentially modeling a set of words, the speaking of which involves making a first and a second articulatory gesture, as pictures corresponding to such words are displayed, in order to induce the subject to attempt to say the modeled words, until the subject is able to produce the constrictions of the oral-pharyngeal cavity associated with both of said articulatory gestures of the words together with vibration of the vocal folds, and the subject is able to produce such words intelligibly. The subject's ability is incrementally expanded using sets of words involving the making of other articulatory gestures until the subject is able to intelligibly produce words involving substantially all of the articulatory gestures used in the language of interest. Positive visual reinforcement is given to the subject for each word that the subject is able to produce intelligibly. For subjects having a level of intelligibility, the ability to produce generative speech is developed, first by displaying a set of pictures depicting actions corresponding to verbs, the speaking of which involves making a first articulatory gesture and modeling or phonetically facilitating the verb corresponding to each of said pictures until the subject is able to produce the verbs. Positive feedback is provided to the subject each time the subject says verb corresponding to one of said displayed pictures by animating said picture to produce the action corresponding to the verb. The subject's ability is expanded using sets of verbs involving the making of other articulatory gestures and further expanded using phrases containing such verbs with the display of corresponding pictures. In the next stage of the method the subject's ability to produce generative language is further expanded with the use of stories. The subject's progress is monitored by uploading and analyzing data including speech samples.

Compositions and methods for the detection and treatment of autism and autistic spectrum disorder are provided.

This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I):and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, tinnitus, status epilepticus.

The present invention relates generally to genetic markers for autism spectrum disorders and other childhood developmental delay disorders, in particular to copy number variant genetic markers for autism spectrum disorders.

Various embodiments of the present invention describe mechanisms configured to monitor, track, and manage symptoms of autism spectrum disorder. According to particular embodiments, a system includes sensors configured to monitor repetitive motion exhibited by a user with an autism spectrum disorder (ASD). The sensors are connected to a processor that is configured to determine whether the repetitive motion exhibited by the user exceeds an autism episode threshold. Once the autism episode threshold has been reached, the processor can access from memory an autism episode alleviation action associated with the user. Materials associated with the autism episode alleviation action can be presented to the user through an output interface, such that presentation of these materials is configured to reduce the severity or duration of the autism episode.